

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND NON-COMPLIANCE OF LISTING RULES

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) hereby announces that Ms. Qi Jingyao (“**Ms. Qi**”) tendered her resignation to the Company in respect of her positions as an independent non-executive Director, chairman of the remuneration and appraisal committee (the “**Remuneration and Appraisal Committee**”) and member of audit committee (the “**Audit Committee**”) of the Company with effect from 26 March 2025 in order to focus on her other personal commitments.

Ms. Qi confirmed that, as at 26 March 2025, she has no disagreement with the Board and there is no matter related to her resignation that needs to be brought to the attention of the Company’s shareholders.

The Board would like to take this opportunity to express its sincere appreciation to Ms. Qi for her invaluable contributions to the Company during her tenure of service.

NON-COMPLIANCE WITH THE LISTING RULES

Following the resignation of Ms. Qi with effect from 26 March 2025, the Board comprises eight members with only two independent non-executive Directors, the Audit Committee of the Company comprises only two members, and the Remuneration and Appraisal Committee of the Company comprises two members with only one independent non-executive Directors. As a result, the Company fails to meet: (i) the requirement under Rule 3.10(1) of the Rules Governing the Listing (the “**Listing Rules**”) of Securities on or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), which stipulates that every board of directors of a listed issuer must include at least three independent non-executive directors; (ii) the requirement under Rule 3.21 of the Listing Rules, which stipulates that the Audit Committee must comprise a minimum of three members; and (iii) the requirement under Rule 3.25 of the Listing Rules, which stipulates that the Remuneration and Appraisal Committee must be

chaired by an independent non-executive director and comprise a majority of independent non-executive directors. The Company is in the process of identifying potential candidates to fill the vacancy of the independent non-executive Director, the Audit Committee and the Remuneration and Appraisal Committee, as soon as possible within three months from the effective date of resignation of Ms. Qi pursuant to Rule 3.11 of the Listing Rules. Further announcement(s) will be made in this regard as and when appropriate in accordance with the requirements of the Listing Rules.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, the PRC, 27 March 2025

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Mr. Zhu Pai as non-executive Directors; and (iii) Dr. Meng Songdong and Mr. Ran Dong as independent non-executive Directors.